NASDAQ: MRSNMersana Therapeutics Inc Stock
$3.34-0.18 (-5.11%)
Updated Apr 18, 2024
MRSN Price
$3.34
Fair Value Price
-$1.21
Market Cap
$405.15M
52 Week Low
$0.80
52 Week High
$9.62
P/E
-2.26x
P/B
10.98x
P/S
7.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.86M
Earnings
-$171.67M
Gross Margin
100%
Operating Margin
-454.75%
Profit Margin
-465.8%
Debt to Equity
5.13
Operating Cash Flow
-$169M
Beta
1.32
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MRSN Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRSN ($3.34) is overvalued by 376.14% relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MRSN ($3.34) is not significantly undervalued (376.14%) relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MRSN due diligence checks available for Premium users.
Be the first to know about important MRSN news, forecast changes, insider trades & much more!
MRSN News
Valuation
MRSN fair value
Fair Value of MRSN stock based on Discounted Cash Flow (DCF)
Price
$3.34
Fair Value
-$1.21
Undervalued by
376.14%
MRSN ($3.34) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MRSN ($3.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MRSN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.26x
Industry
15.68x
Market
41.33x
MRSN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.98x
Industry
5.76x
MRSN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRSN's financial health
Profit margin
Revenue
$10.7M
Net Income
-$19.5M
Profit Margin
-182.6%
MRSN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MRSN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$226.1M
Liabilities
$189.2M
Debt to equity
5.13
MRSN's short-term assets ($214.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRSN's short-term assets ($214.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.0M
Investing
$20.1M
Financing
$92.0k
MRSN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MRSN vs Biotech Stocks
Mersana Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.